

Coronaire spasmen

CORONAIRE SPASMEN = PRINZMETAL ANGINA

1. Andere namen

- Prinzmetal angina
- variant angina

2. Oorzaken

- focale coronaire spasmen
- meestal bij stenosen
- verder sympatische stimulatie zonder parasympatische stimulatie door endogene hormonen.
- thv de coronairen zelf abnormale vasodilatatiefunctie, hypersensitiviteit voor vasoconstrictoren.

3. Diagnostische workup

- kliniek:
 - thoracale pijn retrosternaal, in rust (soms bij koude, stress, hyperventilatie. Soms is een cicardiaans patroon merkbaar, meer specifiek: vooral pijn 's morgens. Vaak uitstraling naar hals, kaak en arm. Verbeterd soms met oefeningen.
 - palpitaties
 - (pre-) syncopaal
 - zelden associatie met migraine of ziekte van Raynaud
 - ook bij personen zonder risicofactoren
 - risicofactoren: ouderdom (mannen tussen 51 en 57), roken, hyperinsulinaemie, insulineresistentie
- anamnese
 - aanleiding?
 - duur?
 - aard?

- Electrocardiogram
 - ST segment: transiente elevatie gevolgd door ST depressie en T-inversie
- Labo
 - CK-MB
 - troponine
 - toxico screening (risico: cocaine)
- Beeldvorming
 - RX-thorax:
 - andere oorzaken: pneumonie? pneumothorax? aortadissectie?
 - fietstest: controversieel. Alleen zichtbaar indien ook een stenose
 - Thallium scintigrafie
- coronarografie met provocatietesten (hyperventilatie, acetylcholine, ergovine) toont vaak milde atherosclerose

4. DD

- cardiovasculair
 - angina pectoris
 - AMI
 - pericarditis
 - mitralisklep prolaps
 - aortadissectie
- longen
 - pneumothorax
 - longembolen
- gastro-intestinaal
 - oesofagaal (spasme, ruptuur, oesofagitis, reflux)
 - maagulcera
- angststoornis

Eerste opvang

- ABC
- monitoring
- IV lijn
- zuurstof
- pulse oximetrie
- aspirine altijd toedienen!

Spoeddienst

- anti-angiosa
 - indicaties: angina pectoris, linker hartfalen (vb longoedeem), hypertensieve crisis
 - contra-indicaties: hypotensie, shock, rechter ventrikelfarct
 - welke producten?
 - Nitraten SL: Nitrolingual (1 dosis spray = 0,4 mg), Cedocard (meerdere dosages! meestal 5 mg)
 - Nitraten IV: Cedocard: 1 amp = 10mg/10ml
 - molsidomine (Corvaton) 1 amp = 20mg/10ml
- calcium antagonisten (indien de anamnes specifiek is)
 - Verapamil (Isoptine, Lodixal):
 - Per os: bij angor 320 à 360 mg/d in 3 giften, Bij aritmie 120 à 480 mg/d, bij AHT 240 à 480 mg/d
 - IV: bij supraventriculaire tachycardie 1 amp (5 mg) traag IV, evtl te herhalen na 10 min
 - Diltiazem (Tildiem)

- Per os: bij angor 1x daags 200 à 300 mg of 3x daags 60 à 120 mg. Bij hypertensie 1x daags 200 à 300 mg

- Heparine of beta-blokkers hebben GEEN nut!

REFERENTIES:

1. PRINZMETAL M, KENNAMER R, MERLISS R, et al. Angina pectoris. I. A variant form of angina pectoris; preliminary report. *Am J Med* 1959; 27:375.
2. Kaski JC, Crea F, Meran D, et al. Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. *Circulation* 1986; 74:1255.
3. Kaski JC, Maseri A, Vejar M, et al. Spontaneous coronary artery spasm in variant angina is caused by a local hyperreactivity to a generalized constrictor stimulus. *J Am Coll Cardiol* 1989; 14:1456.
4. PRINZMETAL M, EKMEKCI A, KENNAMER R, et al. Variantform of angina pectoris, previously undelineated syndrome. *JAMA* 1960; 174:1794.
5. Okumura K, Yasue H, Matsuyama K, et al. Diffuse disorder of coronary artery vasomotility in patients with coronary spastic angina. Hyperreactivity to the constrictor effects of acetylcholine and the dilator effects of nitroglycerin. *J Am Coll Cardiol* 1996; 27:45.
6. De Caterina R, Carpeggiani C, L'Abbate A. A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Evidence against a role for serotonin in the genesis of coronary vasospasm. *Circulation* 1984; 69:889.
7. Winniford MD, Filipchuk N, Hillis LD. Alpha-adrenergic blockade for variant angina: a long-term, double-blind, randomized trial. *Circulation* 1983; 67:1185.
8. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. *Cardiovasc Res* 1999; 43:1029.
9. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. *Circulation* 2000; 101:1319.
10. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. *Circulation* 2002; 105:1545.
11. Nakano T, Osanai T, Tomita H, et al. Enhanced activity of variant phospholipase C-delta1 protein (R257H) detected in patients with coronary artery spasm. *Circulation* 2002; 105:2024.
12. Yasue H, Touyama M, Shimamoto M, et al. Role of autonomic nervous system in the pathogenesis of Prinzmetal's variant form of angina. *Circulation* 1974; 50:534.
13. Sueda S, Ochi N, Kawada H, et al. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. *Am J Cardiol* 1999; 83:1186.
14. Yasue H, Touyama M, Kato H, et al. Prinzmetal's variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: documentation by coronary arteriography. *Am Heart J* 1976; 91:148.
15. Ricci DR, Orlick AE, Cipriano PR, et al. Altered adrenergic activity in coronary arterial spasm: insight into mechanism based on study of coronary hemodynamics and the electrocardiogram. *Am J Cardiol* 1979; 43:1073.
16. Yasue H, Horio Y, Nakamura N, et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. *Circulation* 1986; 74:955.
17. Bertrand ME, Lablanche JM, Tilmant PY, et al. Complete denervation of the heart (autotransplantation) for treatment of severe, refractory coronary spasm. *Am J Cardiol* 1981; 47:1375.
18. Lanza GA, Pedrotti P, Pasceri V, et al. Autonomic changes associated with spontaneous coronary spasm in patients with variant angina. *J Am Coll Cardiol* 1996; 28:1249.
19. Stern S, Bayes de Luna A. Coronary artery spasm: a 2009 update. *Circulation* 2009; 119:2531.

20. Saitoh T, Kishida H, Hanashi A, et al. Coronary hyperreactivity to adrenergic stimulation and increased nocturnal vagal tone trigger coronary vasospasm. *Jpn Circ J* 1998; 62:721.
21. Bertrand ME, Lablanche JM, Tilmant PY. Treatment of Prinzmetal's variant angina. Role of medical treatment with nifedipine and surgical coronary revascularization combined with plexectomy. *Am J Cardiol* 1981; 47:174.
22. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. *Circulation* 1996; 94:266.
23. Kugiyama K, Ohgushi M, Motoyama T, et al. Nitric oxide-mediated flow-dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. *J Am Coll Cardiol* 1997; 30:920.
24. Nakayama M, Yasue H, Yoshimura M, et al. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. *Circulation* 1999; 99:2864.
25. Levin ER. Endothelins. *N Engl J Med* 1995; 333:356.
26. Cox ID, Bøtker HE, Bagger JP, et al. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. *J Am Coll Cardiol* 1999; 34:455.
27. Figueras J, Domingo E, Cortadellas J, et al. Comparison of plasma serotonin levels in patients with variant angina pectoris versus healed myocardial infarction. *Am J Cardiol* 2005; 96:204.
28. Motoyama T, Kawano H, Kugiyama K, et al. Vitamin E administration improves impairment of endothelium-dependent vasodilation in patients with coronary spastic angina. *J Am Coll Cardiol* 1998; 32:1672.
29. Hirashima O, Kawano H, Motoyama T, et al. Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. *J Am Coll Cardiol* 2000; 35:1860.
30. Miyao Y, Kugiyama K, Kawano H, et al. Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina. *J Am Coll Cardiol* 2000; 36:432.
31. Suzuki H, Kawai S, Aizawa T, et al. Histological evaluation of coronary plaque in patients with variant angina: relationship between vasospasm and neointimal hyperplasia in primary coronary lesions. *J Am Coll Cardiol* 1999; 33:198.
32. Hung MJ, Cherng WJ, Yang NI, et al. Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease. *Am J Cardiol* 2005; 96:1484.
33. Sun H, Mohri M, Shimokawa H, et al. Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. *J Am Coll Cardiol* 2002; 39:847.
34. Nobuyoshi M, Abe M, Nosaka H, et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. *Am Heart J* 1992; 124:32.
35. Takaoka K, Yoshimura M, Ogawa H, et al. Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. *Int J Cardiol* 2000; 72:121.
36. Suzuki S, Yoshimura M, Nakayama M, et al. A novel genetic marker for coronary spasm in women from a genome-wide single nucleotide polymorphism analysis. *Pharmacogenet Genomics* 2007; 17:919.
37. Murase Y, Yamada Y, Hirashiki A, et al. Genetic risk and gene-environment interaction in coronary artery spasm in Japanese men and women. *Eur Heart J* 2004; 25:970.
38. Shinozaki K, Suzuki M, Ikebuchi M, et al. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. *Circulation* 1995; 92:1749.
39. Stricker BH. Coronary vasospasm and sumatriptan. *BMJ* 1992; 305:118.
40. Lange RA, Cigarroa RG, Yancy CW Jr, et al. Cocaine-induced coronary-artery vasoconstriction. *N Engl J Med* 1989; 321:1557.
41. Forman MB, Blass M, Jackson EK. Variant angina in the setting of food-borne botulism. *Clin Infect Dis* 2011; 53:1300.
42. Satake K, Lee JD, Shimizu H, et al. Relation between severity of magnesium deficiency and frequency of anginal attacks in men with variant angina. *J Am Coll Cardiol* 1996; 28:897.
43. Kusama Y, Kodani E, Nakagomi A, et al. Variant angina and coronary artery spasm: the clinical

spectrum, pathophysiology, and management. *J Nippon Med Sch* 2011; 78:4.

44. Ogawa H, Yasue H, Oshima S, et al. Circadian variation of plasma fibrinopeptide A level in patients with variant angina. *Circulation* 1989; 80:1617.
45. Heart Disease: A Textbook of Cardiovascular Medicine, 9th ed, Braunwald E. (Ed), Elsevier Saunders, Philadelphia 2011.
46. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. *Circulation* 1993; 87:76.
47. Rosamond W. Are migraine and coronary heart disease associated? An epidemiologic review. *Headache* 2004; 44 Suppl 1:S5.
48. Nakamura Y, Shinozaki N, Hirasawa M, et al. Prevalence of migraine and Raynaud's phenomenon in Japanese patients with vasospastic angina. *Jpn Circ J* 2000; 64:239.
49. Koh KK, Roe IH, Lee MM, et al. Variant angina complicating ergot therapy of migraine. *Chest* 1994; 105:1259.
50. Previtali M, Ardissino D, Barberis P, et al. Hyperventilation and ergonovine tests in Prinzmetal's variant angina pectoris in men. *Am J Cardiol* 1989; 63:17.
51. Matsuda Y, Ozaki M, Ogawa H, et al. Coronary arteriography and left ventriculography during spontaneous and exercise-induced ST segment elevation in patients with variant angina. *Am Heart J* 1983; 106:509.
52. Minoda K, Yasue H, Kugiyama K, et al. Comparison of the distribution of myocardial blood flow between exercise-induced and hyperventilation-induced attacks of coronary spasm: a study with thallium-201 myocardial scintigraphy. *Am Heart J* 1994; 127:1474.
53. Kishida H, Tada Y, Fukuma N, et al. Significant characteristics of variant angina patients with associated syncope. *Jpn Heart J* 1996; 37:317.
54. Enseleit F, Duru F. Long-term continuous external electrocardiographic recording: a review. *Europace* 2006; 8:255.
55. Araki H, Koiwaya Y, Nakagaki O, Nakamura M. Diurnal distribution of ST-segment elevation and related arrhythmias in patients with variant angina: a study by ambulatory ECG monitoring. *Circulation* 1983; 67:995.
56. Lahiri A, Subramanian B, Millar-Craig M, et al. Exercise-induced S-T segment elevation in variant angina. *Am J Cardiol* 1980; 45:887.
57. Song JK, Park SW, Kang DH, et al. Safety and clinical impact of ergonovine stress echocardiography for diagnosis of coronary vasospasm. *J Am Coll Cardiol* 2000; 35:1850.
58. Hamilton KK, Pepine CJ. A renaissance of provocative testing for coronary spasm? *J Am Coll Cardiol* 2000; 35:1857.
59. Yamada T, Okamoto M, Sueda T, et al. Ergonovine-induced alterations in coronary flow velocity preceding onset of occlusive spasm in patients without significant coronary artery stenoses. *Am J Cardiol* 1998; 81:688.
60. Pepine CJ, Feldman RL, Conti CR. Action of intracoronary nitroglycerin in refractory coronary artery spasm. *Circulation* 1982; 65:411.
61. Bertrand ME, LaBlanche JM, Tilmant PY, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. *Circulation* 1982; 65:1299.
62. Sueda S, Saeki H, Otani T, et al. Major complications during spasm provocation tests with an intracoronary injection of acetylcholine. *Am J Cardiol* 2000; 85:391.
63. Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. *Circulation* 2014; 129:1723.
64. Nakao K, Ohgushi M, Yoshimura M, et al. Hyperventilation as a specific test for diagnosis of coronary artery spasm. *Am J Cardiol* 1997; 80:545.
65. Task Force Members, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J* 2013; 34:2949.
66. Miwa K, Fujita M, Miyagi Y. Beneficial effects of smoking cessation on the short-term prognosis for variant angina--validation of the smoking status by urinary cotinine measurements. *Int J Cardiol* 1994;

67. Drugs for the Heart, 4th ed, Opie LH (Ed), WB Saunders, Philadelphia 1995. p.31.
68. Yasue H, Takizawa A, Nagao M, et al. Long-term prognosis for patients with variant angina and influential factors. *Circulation* 1988; 78:1.
69. Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. *Circulation* 1981; 63:844.
70. Lombardi M, Morales MA, Michelassi C, et al. Efficacy of isosorbide-5-mononitrate versus nifedipine in preventing spontaneous and ergonovine-induced myocardial ischaemia. A double-blind, placebo-controlled study. *Eur Heart J* 1993; 14:845.
71. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. *J Am Coll Cardiol* 2007; 49:1289.
72. Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. *J Am Coll Cardiol* 1998; 31:83.
73. Takahashi J, Nihei T, Takagi Y, et al. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. *Eur Heart J* 2015; 36:228.
74. Shin ES, Lee JH, Yoo SY, et al. A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina. *Heart* 2014; 100:1531.
75. Frenneaux M, Kaski JC, Brown M, Maseri A. Refractory variant angina relieved by guanethidine and clonidine. *Am J Cardiol* 1988; 62:832.
76. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. *J Am Coll Cardiol* 2008; 51:1742.
77. Teragawa H, Kato M, Yamagata T, et al. The preventive effect of magnesium on coronary spasm in patients with vasospastic angina. *Chest* 2000; 118:1690.
78. Corcos T, David PR, Bourassa MG, et al. Percutaneous transluminal coronary angioplasty for the treatment of variant angina. *J Am Coll Cardiol* 1985; 5:1046.
79. Gaspardone A, Tomai F, Versaci F, et al. Coronary artery stent placement in patients with variant angina refractory to medical treatment. *Am J Cardiol* 1999; 84:96.
80. Tanabe Y, Itoh E, Suzuki K, et al. Limited role of coronary angioplasty and stenting in coronary spastic angina with organic stenosis. *J Am Coll Cardiol* 2002; 39:1120.
81. Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. *Circulation* 1982; 65:281.
82. Miwa K, Kambara H, Kawai C. Effect of aspirin in large doses on attacks of variant angina. *Am Heart J* 1983; 105:351.
83. Wasson S, Jayam VK. Coronary vasospasm and myocardial infarction induced by oral sumatriptan. *Clin Neuropharmacol* 2004; 27:198.
84. Maseri A, Lanza G. Fluorouracil-induced coronary artery spasm. *Am J Med* 2001; 111:326.
85. Kishida H, Tada Y, Tetsuo Y, et al. A new strategy for the reduction of acute myocardial infarction in variant angina. *Am Heart J* 1991; 122:1554.
86. Bory M, Pierron F, Panagides D, et al. Coronary artery spasm in patients with normal or near normal coronary arteries. Long-term follow-up of 277 patients. *Eur Heart J* 1996; 17:1015.
87. Walling A, Waters DD, Miller DD, et al. Long-term prognosis of patients with variant angina. *Circulation* 1987; 76:990.
88. Miwa K, Nakagawa K, Yoshida N, et al. Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm. *J Am Coll Cardiol* 2000; 35:1200.
89. Myerburg RJ, Kessler KM, Mallon SM, et al. Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. *N Engl J Med* 1992; 326:1451.
90. Matsue Y, Suzuki M, Nishizaki M, et al. Clinical implications of an implantable cardioverter-defibrillator in patients with vasospastic angina and lethal ventricular arrhythmia. *J Am Coll Cardiol* 2012; 60:908.

91. Ong P, Athanasiadis A, Borgulya G, et al. 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up. *J Am Coll Cardiol* 2011; 57:147.
92. Chevalier P, Dacosta A, Defaye P, et al. Arrhythmic cardiac arrest due to isolated coronary artery spasm: long-term outcome of seven resuscitated patients. *J Am Coll Cardiol* 1998; 31:57.
93. Meisel SR, Mazur A, Chetboun I, et al. Usefulness of implantable cardioverter-defibrillators in refractory variant angina pectoris complicated by ventricular fibrillation in patients with angiographically normal coronary arteries. *Am J Cardiol* 2002; 89:1114.
94. Takagi Y, Takahashi J, Yasuda S, et al. Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese Coronary Spasm Association. *J Am Coll Cardiol* 2013; 62:1144.

Voeg een nieuwe reactie toe

[Login](#) [1] of [registreer](#) [2] om te kunnen reageren

Bron-URL: <https://medicsformedics.nl/nl/coronaire-spasmen>

Links

[1] <https://medicsformedics.nl/nl/user/login?destination=node/%23comment-form>

[2] <https://medicsformedics.nl/nl/user/register?destination=node/%23comment-form>